All Biomarkers

    NfL (Neurofilament Light Chain)

    Neurological
    Neurodegeneration
    pg/mL

    Neurofilament light chain (NfL) is a structural protein released into the blood when nerve axons are damaged. A longevity practice tracks this emerging marker because rising levels signal ongoing neurodegeneration across conditions from Alzheimer's to multiple sclerosis, and can reflect overall brain aging.

    What It Measures

    Neurofilament light chain (NfL) is a core structural protein of neuronal axons that is released into the blood when axons are injured. Plasma NfL is a sensitive but non-specific marker of neuro-axonal damage across many conditions (Alzheimer's and other dementias, multiple sclerosis, ALS, traumatic brain injury, stroke) and rises gradually with normal brain aging.

    Optimal vs. Lab Range

    Longevity Optimal
    At or below the age-adjusted reference interval for the reporting assay.

    Target range for optimal health and longevity based on research.

    Standard Lab
    Age-dependent and assay-specific; one-sided upper reference limits rise with age (e.g., ~8-10 pg/mL in the 20s to ~35-40 pg/mL by the 70s in cognitively healthy adults).

    Population-based reference range from standard labs.

    Why It Matters

    Plasma NfL is one of the most sensitive available blood markers of ongoing neuro-axonal injury, and higher or rising levels are associated with faster cognitive decline, brain atrophy and neurodegenerative disease across cohorts. Because it is disease-non-specific, its chief value is as a longitudinal "smoke detector": a normal, stable NfL is reassuring, while a rising trajectory flags active neuronal injury warranting evaluation. NfL concentrations increase with age (roughly 2-3% per year in cognitively healthy adults), so results must be interpreted against age-specific reference intervals rather than a single cutoff. For a longevity practice, serial NfL complements p-tau and GFAP by capturing the intensity of neuronal injury and tracking response to risk-factor modification.

    When Low

    Low/age-appropriate NfL: no evidence of significant active neuro-axonal injury at the time of testing.

    When Optimal

    At or below the age-adjusted reference: reassuring. Serial testing on the same platform helps establish a personal baseline and detect meaningful change.

    When High

    Above the age-adjusted reference, or a clear upward trend: suggests active neuro-axonal injury. Interpret in clinical context; evaluate for treatable causes and consider neurology referral. NfL is non-specific and does not by itself identify the underlying disease.

    How to Optimize

    NfL is a downstream signal of neuronal injury, so the aim is to reduce the drivers of that injury: control vascular risk factors (blood pressure, glucose, ApoB, smoking), stay physically active, prioritize sleep, limit alcohol and head-injury exposure, and treat any underlying neurological condition. Trends matter more than a single value; retest on the same assay to compare. This content is educational and not a substitute for medical advice.

    Key Interventions & Linked Compounds

    Strong (9/10)

    Key Interventions

    Vascular risk control (BP
    glucose
    ApoB)
    aerobic exercise
    sleep
    alcohol moderation
    head-injury avoidance
    treat underlying neurological disease.

    Linked Compounds & Supplements

    Omega-3
    creatine
    exercise.

    Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

    Ordering Notes

    Specimen

    High-sensitivity plasma assay (SIMOA)

    Patient prep

    No fasting required. Maintain usual diet and medications unless advised.

    Recommended cadence

    Baseline then periodic (e.g., every 12 months) or as clinically indicated; compare on the same assay

    Reporting unit

    pg/mL

    Pre-analytic notes

    Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

    Available panels

    High-sensitivity plasma assay (SIMOA)
    Plasma/serum immunoassay

    Recommended Follow-Up Actions

    1. 1

      Confirm the result is reliable

      Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift NfL (Neurofilament Light Chain).

    2. 2

      Compare against optimal, not just lab range

      Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.

    3. 3

      Pair with related markers

      Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.

    4. 4

      Discuss interventions with a clinician

      Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.

    5. 5

      Re-test on a defined cadence

      If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.

    Testing Information

    Recommended Frequency

    Baseline then periodic (e.g., every 12 months) or as clinically indicated; compare on the same assay

    Fasting Requirement

    No fasting required

    Available Test Types

    High-sensitivity plasma assay (SIMOA)
    Plasma/serum immunoassay
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation